Central vagotonic effect (blocking M1 acetylcholine receptors in parasympathetic ganglion controlling SA node) of atropine which, at higher doses, is masked by muscarinic (M2 acetylcholine receptors) blockade at the sinoatrial node. The initial low dose of atropine may not be sufficient to ensure adequate peak concentration in peripheral tissues.
Dosage <0.5 mg
Scopolamine in low doses is also noted to result in paradoxical bradycardia. Scopolamine 0.1-0.2 mg usually causes more slowing than atropine.
In the latest 2020 AHA update the recommended single dose administration of atropine was increased from 0.5 mg to 1 mg based on data suggesting that at low doses, atropine may cause paradoxical bradycardia.
An article recommended the use of doses of 0.01 and 0.02 mg/kg rather than 0.1 mg as a minimum dose recommendation of atropine to prevent overdose in infants <5 kg body weight.
Atropine-induced bradycardia may be especially difficult to manage in patients who are morbidly obese or post cardiac transplantation.
Reference